1. Anonymous Guidance for industry and FDA staff – class II special controls guidance document: repetitive transcranial magnetic stimulation (rTMS) systems. US Food and Drug Administration. 2011; Document number 1728.
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm265269.htm
2. Anonymous General wellness: policy for low risk devices – guidance for industry and Food and Drug Administration staff. U.S. Food and Drug Administration. 2015; Document number 1300013.
http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm429674.pdf
3. Anonymous Information for patients. International Society for Magnetic Resonance in Medicine. 2016; Available online,
http://www.ismrm.org/resources/information-for-patients/
4. Asashima M, Shimada K, Pfeiffer CJ. Magnetic shielding induces early developmental abnormalities in the newt, Cynopspyrrhogaster. Bioelectromagnetics. 1991;12:215–24.
5. Bassett CA, Pawluk RJ, Pilla AA. Acceleration of fracture repair by electromagnetic fields. A surgically noninvasive method. Ann N Y Acad Sci. 1974a;238:242–62.